Compare Stocks

Date Range: 

 OrganogenesisPacira BioSciencesDeciphera PharmaceuticalsRocket PharmaceuticalsCorcept Therapeutics
SymbolNASDAQ:ORGONASDAQ:PCRXNASDAQ:DCPHNASDAQ:RCKTNASDAQ:CORT
Price Information
Current Price$21.15$63.25$34.33$43.77$21.10
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.02.11.81.41.8
Analysis Score1.53.44.43.52.3
Community Score2.62.92.52.92.7
Dividend Score0.00.00.00.00.0
Ownership Score0.80.01.70.81.7
Earnings & Valuation Score0.04.40.60.02.5
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$16.50$79.36$73.00$59.18$24.00
% Upside from Price Target-21.99% downside25.48% upside112.64% upside35.21% upside13.74% upside
Trade Information
Market Cap$2.71 billion$2.78 billion$1.99 billion$2.70 billion$2.46 billion
Beta1.841.271.492.051.04
Average Volume824,795480,297453,821482,502554,552
Sales & Book Value
Annual Revenue$260.98 million$421.03 million$25 millionN/A$306.49 million
Price / Sales10.396.6179.60N/A8.03
CashflowN/A$1.49 per shareN/AN/A$0.63 per share
Price / CashN/A42.56N/AN/A33.26
Book Value$0.59 per share$8.51 per share$10.71 per share$6.10 per share$3.25 per share
Price / Book35.857.433.21N/A6.49
Profitability
Net Income$-40,450,000.00$-11,020,000.00$-192,260,000.00$-77,270,000.00$94.18 million
EPS($0.42)$0.86($4.48)($1.58)$0.77
Trailing P/E RatioN/A22.27N/AN/A23.71
Forward P/E RatioN/A21.96N/AN/A22.93
P/E GrowthN/A0.82N/AN/AN/A
Net Margins-1.61%29.95%N/AN/A30.73%
Return on Equity (ROE)-10.03%10.71%-45.02%-35.81%25.38%
Return on Assets (ROA)-2.22%4.88%-40.12%-27.52%23.16%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.54%0.78%N/A0.25%N/A
Current Ratio1.95%7.63%9.34%7.30%10.77%
Quick Ratio1.50%6.84%9.26%7.30%10.65%
Ownership Information
Institutional Ownership Percentage4.62%N/A73.61%N/A75.44%
Insider Ownership Percentage57.20%5.80%7.02%41.40%16.40%
Miscellaneous
Employees91062435091236
Shares Outstanding128.21 million44.03 million57.96 million61.78 million116.63 million
Next Earnings Date5/10/2021 (Confirmed)8/5/2021 (Estimated)8/3/2021 (Estimated)5/12/2021 (Estimated)8/3/2021 (Estimated)
OptionableNot OptionableOptionableOptionableOptionableOptionable
SourceHeadline
Corcept Therapeutics Incorporated (NASDAQ:CORT) Is an Exciting StockCorcept Therapeutics Incorporated (NASDAQ:CORT) Is an Exciting Stock
stocksregister.com - May 8 at 7:37 PM
Corcepts (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/YCorcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
nasdaq.com - May 7 at 1:38 PM
Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue EstimatesCorcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates
finance.yahoo.com - May 6 at 10:36 PM
Corcept: Q1 Earnings Snapshot | Raleigh News & ObserverCorcept: Q1 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - May 6 at 5:36 PM
Corcept: Q1 Earnings SnapshotCorcept: Q1 Earnings Snapshot
sfgate.com - May 6 at 5:36 PM
Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian CancerAddition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer
finance.yahoo.com - May 6 at 5:36 PM
Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)
finance.yahoo.com - May 6 at 5:36 PM
Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial ResultsCorcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results
finance.yahoo.com - May 6 at 5:36 PM
Corcept Therapeutics Stock Is Believed To Be Modestly OvervaluedCorcept Therapeutics Stock Is Believed To Be Modestly Overvalued
ca.finance.yahoo.com - May 5 at 9:34 PM
Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - May 5 at 11:33 AM
CORT Crosses Below Key Moving Average LevelCORT Crosses Below Key Moving Average Level
nasdaq.com - May 4 at 2:06 PM
Reviewing Corcept Therapeutics (NASDAQ:CORT) and Intec Pharma (NASDAQ:NTEC)Reviewing Corcept Therapeutics (NASDAQ:CORT) and Intec Pharma (NASDAQ:NTEC)
americanbankingnews.com - May 4 at 12:14 AM
Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to DeclineEarnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline
finance.yahoo.com - April 26 at 1:55 PM
Imagine Holding Corcept Therapeutics (NASDAQ:CORT) Shares While The Price Zoomed 398% HigherImagine Holding Corcept Therapeutics (NASDAQ:CORT) Shares While The Price Zoomed 398% Higher
finance.yahoo.com - April 5 at 8:06 AM
Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report?Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report?
finance.yahoo.com - March 25 at 12:29 PM
Corcept (CORT) Begins Adrenal Cancer Study on RelacorilantCorcept (CORT) Begins Adrenal Cancer Study on Relacorilant
finance.yahoo.com - March 16 at 1:45 PM
Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in ...Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in ...
apnews.com - March 15 at 12:36 PM
Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol ExcessCorcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess
finance.yahoo.com - March 15 at 7:35 AM
Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer;Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer;
apnews.com - March 1 at 8:00 PM
Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business OfficerCorcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer
finance.yahoo.com - March 1 at 8:00 PM
Corcept (CORT) Q4 Earnings In Line, Revenues Miss EstimatesCorcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates
nasdaq.com - February 24 at 1:44 PM
Corcept: 4Q Earnings Snapshot | Raleigh News & ObserverCorcept: 4Q Earnings Snapshot | Raleigh News & Observer
newsobserver.com - February 23 at 7:32 PM
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial ResultsCorcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results
finance.yahoo.com - February 23 at 7:32 PM
Trade Alert: The CFO & Secretary Of Corcept Therapeutics Incorporated (NASDAQ:CORT), Gary Robb, Has Sold Some Shares RecentlyTrade Alert: The CFO & Secretary Of Corcept Therapeutics Incorporated (NASDAQ:CORT), Gary Robb, Has Sold Some Shares Recently
nasdaq.com - February 21 at 8:55 AM
Corcept Therapeutics Incorporateds (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals?Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals?
finance.yahoo.com - February 19 at 8:02 AM
DateCompanyBrokerageAction
3/23/2021OrganogenesisSVB LeerinkBoost Price Target
3/12/2021OrganogenesisCredit Suisse GroupBoost Price Target
1/14/2021OrganogenesisBTIG ResearchBoost Price Target
9/21/2020OrganogenesisOppenheimerReiterated Rating
5/5/2021Pacira BioSciencesNorthland SecuritiesLower Price Target
4/15/2021Pacira BioSciencesBerenberg BankInitiated Coverage
3/8/2021Pacira BioSciencesHC WainwrightBoost Price Target
2/26/2021Pacira BioSciencesBarclaysBoost Price Target
1/20/2021Pacira BioSciencesPiper SandlerBoost Price Target
1/8/2021Pacira BioSciencesNeedham & Company LLCBoost Price Target
1/6/2021Pacira BioSciencesRoyal Bank of CanadaBoost Price Target
11/2/2020Pacira BioSciencesWedbushLower Price Target
9/30/2020Pacira BioSciencesJefferies Financial GroupBoost Price Target
8/14/2020Pacira BioSciencesTruistBoost Price Target
12/2/2020Deciphera PharmaceuticalsStifel NicolausInitiated Coverage
9/14/2020Deciphera PharmaceuticalsJPMorgan Chase & Co.Initiated Coverage
6/12/2020Deciphera PharmaceuticalsGuggenheimReiterated Rating
5/18/2020Deciphera PharmaceuticalsSunTrust BanksBoost Price Target
5/7/2020Deciphera PharmaceuticalsNomura InstinetDowngrade
1/21/2020Deciphera PharmaceuticalsNomura SecuritiesBoost Price Target
1/15/2020Deciphera PharmaceuticalsJMP SecuritiesReiterated Rating
12/15/2020Rocket PharmaceuticalsUBS GroupInitiated Coverage
12/10/2020Rocket PharmaceuticalsEvercore ISIBoost Price Target
12/8/2020Rocket PharmaceuticalsChardan CapitalBoost Price Target
10/16/2020Rocket PharmaceuticalsLifesci CapitalReiterated Rating
8/9/2020Rocket PharmaceuticalsCowenReiterated Rating
8/5/2020Rocket PharmaceuticalsCi CapitalReiterated Rating
6/25/2020Rocket PharmaceuticalsBank of AmericaInitiated Coverage
5/6/2020Rocket PharmaceuticalsWilliam BlairReiterated Rating
2/21/2020Corcept TherapeuticsCantor FitzgeraldReiterated Rating
2/5/2019Corcept TherapeuticsB. RileySet Price Target
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.